These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16934458)

  • 21. Allosteric small-molecule kinase inhibitors.
    Wu P; Clausen MH; Nielsen TE
    Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
    Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
    J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.
    Fischmann TO; Smith CK; Mayhood TW; Myers JE; Reichert P; Mannarino A; Carr D; Zhu H; Wong J; Yang RS; Le HV; Madison VS
    Biochemistry; 2009 Mar; 48(12):2661-74. PubMed ID: 19161339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators.
    Zhang L; Rogers BN; Duplantier AJ; McHardy SF; Efremov I; Berke H; Qian W; Zhang AQ; Maklad N; Candler J; Doran AC; Lazzaro JT; Ganong AH
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5493-6. PubMed ID: 18812259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
    Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads.
    Kotthaus J; Schade D; Muschick N; Beitz E; Clement B
    Bioorg Med Chem; 2008 Dec; 16(24):10205-9. PubMed ID: 19013076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia.
    Scholl FA; Dumesic PA; Barragan DI; Harada K; Bissonauth V; Charron J; Khavari PA
    Dev Cell; 2007 Apr; 12(4):615-29. PubMed ID: 17419998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2007; 27(3B):1387-92. PubMed ID: 17595752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
    Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
    J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
    J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective transcriptional down-regulation of human rhinovirus-induced production of CXCL10 from airway epithelial cells via the MEK1 pathway.
    Zaheer RS; Koetzler R; Holden NS; Wiehler S; Proud D
    J Immunol; 2009 Apr; 182(8):4854-64. PubMed ID: 19342664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
    Edwards PD; Albert JS; Sylvester M; Aharony D; Andisik D; Callaghan O; Campbell JB; Carr RA; Chessari G; Congreve M; Frederickson M; Folmer RH; Geschwindner S; Koether G; Kolmodin K; Krumrine J; Mauger RC; Murray CW; Olsson LL; Patel S; Spear N; Tian G
    J Med Chem; 2007 Nov; 50(24):5912-25. PubMed ID: 17985862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic analysis highlights the key role of TLR2/NF-kappaB/MAP kinase signaling for IL-8 induction by macrophage-like THP-1 cells under influence of Borrelia burgdorferi lysates.
    Sadik CD; Hunfeld KP; Bachmann M; Kraiczy P; Eberhardt W; Brade V; Pfeilschifter J; Mühl H
    Int J Biochem Cell Biol; 2008; 40(11):2508-21. PubMed ID: 18571457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
    Jones CD; Andrews DM; Barker AJ; Blades K; Byth KF; Finlay MR; Geh C; Green CP; Johannsen M; Walker M; Weir HM
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6486-9. PubMed ID: 18986805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.
    Nishimura T; Iino T; Mitsuya M; Bamba M; Watanabe H; Tsukahara D; Kamata K; Sasaki K; Ohyama S; Hosaka H; Futamura M; Nagata Y; Eiki J
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1357-60. PubMed ID: 19188063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel orally bioavailable gamma-secretase inhibitors with excellent in vivo activity.
    Keown LE; Collins I; Cooper LC; Harrison T; Madin A; Mistry J; Reilly M; Shaimi M; Welch CJ; Clarke EE; Lewis HD; Wrigley JD; Best JD; Murray F; Shearman MS
    J Med Chem; 2009 Jun; 52(11):3441-4. PubMed ID: 19432431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MAP kinase: it's been longer than fifteen minutes.
    Sturgill TW
    Biochem Biophys Res Commun; 2008 Jun; 371(1):1-4. PubMed ID: 18406346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.